Clinical Research Directory

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female aged ≥18 years living with HIV 4. Admitted to hospital with 1) clinical concern for infection; 2) ≥2 qSOFA score criteria (Glasgow Coma Scale score \<15, a respiratory rate ≥22, or a systolic blood pressure ≤90 mmHg or a mean arterial pressure of ≤65 mmHg) 5. Resident within a pre-defined geographic area to ensure TB clinic follow-up 6. For females of reproductive potential: use of highly effective contraception through 28 days Exclusion Criteria: 1. Known active TB or receiving anti-TB therapy 2. Pregnancy or lactation. Women will undergo urine pregnancy screening. Pregnant women will be excluded due to the possible toxicity and teratogenicity of high dose rifampin and isoniazid included in anti-TB therapy as well as possible teratogenicity of dolutegravir which is recommended as first-line antiretroviral therapy in this study. 3. Known allergic reactions to the components of the anti-TB therapy 4. Treatment with another investigational drug or other intervention within one month 5. Known liver disease 6. Alcohol use \> 14 standardized drinks per week and/or \> 4 drinks per day for men and \>7 standardized drinks per week and/or \>3 drinks per day for women, defined as 14 grams of ethanol, as found in example 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of 80 proof spirits 7. Positive serum cryptococcal antigen test 8. Current treatment with a drug known to have significant interaction with anti-TB therapy